Amgen agrees not to seek quick close to Horizon acquisition
Reuters
Published May 18, 2023 08:54AM ET
Updated May 19, 2023 02:50PM ET
WASHINGTON (Reuters) - Amgen Inc (NASDAQ:AMGN) has agreed not to quickly close on its $27.8 billion acquisition of Horizon Therapeutics (NASDAQ:HZNP) after the U.S. Federal Trade Commission (FTC) filed suit to block the deal.
A U.S. district court judge issued a temporary restraining order late on Wednesday after the two companies and the FTC reached an agreement that both sides said in a joint filing would permit a full briefing and "less-compressed consideration" by the court of the FTC request.
Absent an agreement, Amgen could have sought to close the deal as early as Monday.
Under the order, Amgen and Horizon will not close their transaction until the earlier of Sept. 15, or the second business day after the court rules on the FTC's request for a preliminary injunction.
California-based Amgen, which had earlier hoped to close the deal in the first half of this year, had said on Tuesday it would work with the court in a bid to complete the transaction by mid-December.
In its lawsuit the FTC said it believed Amgen could leverage its big selling drugs to pressure insurance companies and pharmacy benefit managers to favor Horizon's two key products - the fast-growing thyroid eye disease treatment Tepezza and gout drug Krystexxa - over potential competitors.
Amgen said it had made an offer to the FTC in the hope of resolving the issue. "We committed that we would not bundle the Horizon products raised as issues," Amgen said in a statement.
Reuters reported on Thursday that the FTC faces an uphill battle in its fight against the deal with an untested argument, three antitrust experts said.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.